The landscape of Alzheimer's treatment is evolving rapidly. At the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference, researchers presented breakthrough data on treatments that go far beyond amyloid-clearing therapies like Leqembi and Kisunla.

In this podcast episode, I break down seven treatments that could be available—or very close to available—in 2026:

1. Remternetug - Anti-tau antibody that could be combined with existing treatments

2. ALZ-801 - Oral amyloid blocker (no infusions required)

3. Masitinib - Anti-inflammatory targeting neuroinflammation

4. Fosgonimeton - Synaptic restoration therapy

5. Gantenerumab - High-dose amyloid therapy showing renewed promise

6. Semaglutide (Ozempic) - Repurposed diabetes drug with neuroprotective effects

7. Combination therapy trials - Multiple mechanisms working together

We're also seeing a major shift toward earlier intervention—treating people before symptoms appear using biomarker testing, blood tests, and PET scans.

What this means for families:

• More treatment options beyond current FDA-approved therapies

• Oral medications in development (reducing infusion burden)

• Different mechanisms for patients who don't respond to amyloid-clearing therapies

• Earlier intervention strategies that could preserve more function

What you should do now:

• Maximize current treatment options (Leqembi, Kisunla)

• Consider clinical trial participation

• Explore biomarker testing if you're at risk

• Stay informed about the treatment pipeline

• Connect with research centers and advocacy organizations

Listen to the full episode for detailed analysis of each treatment, FDA approval timelines, patient eligibility criteria, and actionable steps you can take today.

This episode is a love letter to every person who has ever said "yes" to Alzheimer's research when outcomes were uncertain. Behind every breakthrough treatment stand volunteers whose courage makes medical advances possible.

Episode highlights:

✓ Why clinical trial volunteers give "the ultimate gift"

✓ What participation actually requires (trust, time, risk, hope)

✓ My mother's 2019 decision to enroll in Leqembi trials

✓ Milestones her courage gave our family

✓ Why her gift extends to people she'll never meet

✓ How one person's sacrifice ripples across generations

✓ Concrete ways to honor and support clinical research

The numbers that matter:

• 1,795 Clarity AD participants made Leqembi possible

• 1,736 TRAILBLAZER-ALZ 2 participants made Kisunla real

• Thousands currently enrolling in trials for future treatments

• One person's courage = changed trajectory for millions

What clinical trial participation requires:

→ Trust in uncertain outcomes

→ Frequent MRIs and brain scans → Regular multi-hour infusions

→ Cognitive testing highlighting decline → ARIA risk acceptance

→ Months or years of commitment

→ Hope for others without guaranteed personal benefit

This episode honors every volunteer—past, present, and future—who chose courage over fear.

Timeline: 0:00 - Cold open: The ultimate gift 2:00 - Why this gift matters 4:00 - My mother's decision (2019) 8:30 - What her courage gave us 14:00 - The unnamed thousands 18:30 - Science behind the sacrifice 22:00 - Gratitude in the season of giving 26:00 - How we honor this gift 28:30 - Closing: You're not alone

To every clinical trial volunteer: Thank you. Your gift is why we have hope. ❤️

#AlzheimersClinicalTrials #Leqembi #Kisunla #MedicalResearch #ClinicalTrialVolunteers #AlzheimersBreakthrough #UltimateGift #AlzheimersPodcast

After 6 years as my mother's study partner in the Leqembi clinical trial, I'm pulling back the curtain on what really happens in Alzheimer's research. This isn't theory—this is lived experience.

In This Episode: ⏱️ 0:00 - Introduction: Why clinical trials feel mysterious ⏱️ 3:45 - How Alzheimer's trials actually work ⏱️ 12:20 - The truth about placebos ⏱️ 18:15 - Who qualifies for trials & why ⏱️ 24:30 - The study partner role that healed my helplessness ⏱️ 31:10 - Safety protocols that build trust ⏱️ 37:45 - Myths we need to bust ⏱️ 43:20 - How to find trials + questions to ask ⏱️ 49:00 - From trial to treatment: Mom's drug is now FDA-approved

Resources Mentioned:

• Alzheimer's Association TrialMatch

• ClinicalTrials.gov

• Memory Treatment Advisors discovery calls: memorytreatmentadvisors.com/schedule

The drug my mom tested (BAN2401) is now FDA-approved Leqembi—proof that trial participation creates real-world impact for families nationwide.

Whether you're considering a trial or simply want to understand your options, this episode provides the clarity you deserve.After 6 years as my mother's study partner in the Leqembi clinical trial, I'm pulling back the curtain on what really happens in Alzheimer's research. This isn't theory—this is lived experience.

Resources Mentioned:

• Alzheimer's Association TrialMatch

• ClinicalTrials.gov

• Memory Treatment Advisors discovery calls: memorytreatmentadvisors.com/schedule

The drug my mom tested (BAN2401) is now FDA-approved Leqembi—proof that trial participation creates real-world impact for families nationwide.

Whether you're considering a trial or simply want to understand your options, this episode provides the clarity you deserve.